NHS
North East and
North Cumbria

Recommendations from February 2023 Medicines Committee

Summary of decisions made regarding new product requests and formulary amendments approved at a meeting of the ICB Executive Committee on Tuesday 14th March 2023

Recommendations with significant financial/commissioning impact

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
Nil			

Recommendations without significant financial/commissioning impact

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
NENC Guidance: Management of Symptomatic Recurrent Uncomplicated Urinary Tract Infections in Adult Women	Jan 2023	New ICB guidance	Approve. Developed by the AMS workstream and approved by the ICS AMR board plus January 2023 NTAG. Recurrent UTI ICS Final Guidance Jan 2
TA838: Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne considers that, at this time, there is not enough evidence to provide a submission for this appraisal.	02/11/22	Not listed.	No action: terminated appraisal.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA839: Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. Novartis considers that the technology is unlikely to be a cost-effective use of NHS resources based on the current price in existing indications.	16/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.
TA840: Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. Novartis considers that the technology is unlikely to be a cost-effective use of NHS resources based on the current price in existing indications.	16/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen has confirmed that it does not intend to make an evidence submission for the appraisal. Amgen considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population.	22/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.
TA842: Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory follicular lymphoma in adults after 2 or more therapies. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. Novartis considers that the technology is unlikely to be a cost-effective use of NHS resources based on the current price in existing indications.	22/11/22	Listed as a RED drug for other indications	No action: terminated appraisal.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and
North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA843: Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of luspatercept for treating anaemia caused by beta-thalassaemia in adults. This is because BMS has confirmed that it does not intend to make an evidence submission for the appraisal. BMS considers that there is not enough evidence to provide a submission for this appraisal.	24/11/22	Not listed.	No action: terminated appraisal.
TA844: Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	24/11/22	Not listed.	No action: terminated appraisal.
TA845: Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of mepolizumab for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over. This is because GSK has confirmed that it does not intend to make an evidence submission for the appraisal. GSK considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this rare disease population.	29/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA846: Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of mepolizumab for treating hypereosinophilic syndrome in adults. This is because GSK has confirmed that it does not intend to make an evidence submission for the appraisal. GSK considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this rare disease population.	29/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.
TA847: Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) **Commissioning: ICS** NICE is unable to make a recommendation about the use in the NHS of mepolizumab for treating severe chronic rhinosinusitis with nasal polyps in adults. GSK has confirmed that it does not intend to make an evidence submission for this appraisal. This is because the technology will not be launched in the UK for treating this indication.	29/11/22	Listed as a RED drug for other indications.	No action: terminated appraisal.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA848: Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation about the use in the NHS of cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. Sanofi has confirmed that it does not intend to make a submission for the appraisal. This is because the technology will not be launched in the UK for treating this indication.	1/12/22	Not listed.	No action: terminated appraisal.
TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma **Commissioning: NHSE** Cabozantinib is recommended as an option for treating advanced hepatocellular carcinoma in adults who have had sorafenib, only if: • they have Child–Pugh grade A liver impairment and an ECOG performance status of 0 or 1, and • the company provides it according to the commercial arrangement.	14/12/22	Listed as a RED drug for other indications.	Add to formulary as a RED drug in this indication, with a link to TA849.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA850: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy **Commissioning: NHSE** Amivantamab is not recommended, within its marketing authorisation, for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.	14/12/22	Not listed.	Add to "not approved" list.
TA851: Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer **Commissioning: NHSE** Pembrolizumab is recommended, within its marketing authorisation, as an option with chemotherapy for neoadjuvant treatment and then continued alone as adjuvant treatment after surgery for adults with triple-negative: • early breast cancer at high risk of recurrence or • locally advanced breast cancer. It is recommended only if the company provides pembrolizumab according to the commercial arrangement.	14/12/22	Listed as a RED drug for other indications.	Add to formulary as a RED drug in this indication, with a link to TA851.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and North Cumbria

Recommendations from February 2023 Medicines Committee

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/ guidance relevance	Decision
TA852: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments **Commissioning: NHSE** Trifluridine–tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.	14/12/22	Listed as a RED drug for other indications.	Add to formulary as a RED drug in this indication, with a link to TA852.
TA853: Avatrombopag for treating primary chronic immune thrombocytopenia **Commissioning: ICS** Avatrombopag is recommended, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults. It is only recommended if the company provides it according to the commercial arrangement.	15/12/22	Listed as a RED drug for other indications.	Add to formulary as a RED drug in this indication, with a link to TA853.
TA854: Esketamine nasal spray for treatment-resistant depression **Commissioning: ICS** Esketamine nasal spray with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is not recommended, within its marketing authorisation, for treatment-resistant depression that has not responded to at least 2 different antidepressants in the current moderate to severe depressive episode in adults.	14/12/22	Not listed.	Add to “not approved” list.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.

NHS
North East and
North Cumbria

Recommendations from February 2023 Medicines Committee

Recommendations from the NENC Area Prescribing Committees approved at March 2023 meeting of the North East & North Cumbria ICB Executive Committee.

	Recommendations from the APC
Sunderland and South Tyneside APC	 South Tyneside and Sunderland Area Pre
County Durham and Tees APC	 CD&T APC January 2023 Decision Summ
North of Tyne, Gateshead and North Cumbria APC	 NoTGNC APC January-2023-Decisic

For information

NTAG work plan	 NTAG workplan Jan23.pdf

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.